Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Antibody-drug Conjugate
100%
Janus Kinase Inhibitors
100%
Hematopoietic Stem Cell Transplantation
83%
Janus Kinase 1 (JAK1)
50%
Natural Killer Cells
33%
Graft-versus-host Disease (GvHD)
33%
T Cells
33%
Transplantation Conditioning
33%
Allogeneic HSCT
33%
Baricitinib
33%
Acute Leukemia
16%
Hematological Diseases
16%
Syngeneic
16%
Clinical Application
16%
Pharmacologic
16%
Survival Function
16%
Cell Survival
16%
Interleukin-15 (IL-15)
16%
Effector Function
16%
C-kit
16%
Graft-versus-leukemia Effect
16%
Mechanistic Studies
16%
Myeloid Lineage
16%
Alloreactivity
16%
Solid Organ Transplantation
16%
Targeting Antibodies
16%
CD45
16%
Donor chimerism
16%
Multilineage
16%
Donor Lymphocyte Infusion
16%
Infusion Model
16%
Conditioning Strategy
16%
Medicine and Dentistry
Antibody-Drug Conjugate
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Janus Kinase Inhibitor
100%
Hematopoietic Stem Cell Transplantation
83%
Janus Kinase 1
50%
Natural Killer Cell
33%
T Cell
33%
Conditioning
33%
Transplantation Conditioning
33%
Baricitinib
33%
Cell Survival
16%
Immunotherapy
16%
Graft Versus Host Reaction
16%
Acute Leukemia
16%
Chimera
16%
Solid Organ Transplantation
16%
Graft Versus Leukemia Effect
16%
Alloimmunity
16%
Interleukin 15
16%
Donor Lymphocyte Infusion
16%
Diseases
16%
Immunology and Microbiology
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Antibody Drug Conjugate
100%
Hematopoietic Stem Cell Transplantation
83%
Conditioning
66%
Natural Killer Cell
33%
T Cell
33%
Graft-Versus-Host Disease
16%
Myeloid
16%
Chimera
16%
Syngenic
16%
Lineages
16%
Cell Survival
16%
Immunotherapy
16%
Interleukin 15
16%
Alloimmunity
16%
Solid Organ Transplantation
16%
Lymphocyte
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antibody Drug Conjugate
100%
Janus Kinase Inhibitor
100%
Janus Kinase 1
50%
Baricitinib
33%
Leukemia
16%
Immunotherapy
16%
Graft Versus Host Reaction
16%
Acute Leukemia
16%
Interleukin 15
16%
Diseases
16%